Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
Bristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News. Krazati had received accelerated approval in 2024 in this setting. But a Phase ...
April 30, 2026 02:37 PM EDT R&D Bristol Myers' Krazati fails confirmatory trial in colorectal cancer, putting approval at risk Max Gelman Senior Editor Bristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News. Krazati had received … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that